Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734188 | 0.86 | HCAR3 (0.49) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL2042231 | 0.85 | HCAR3 (0.50) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL29788097 | 0.85 | HCAR3 (0.50) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL8595311 | 0.85 | HCAR3 (0.61) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL4596038 | 0.83 | HCAR3 (0.59) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL976946 | 0.82 | NNMT (0.55) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL1778519 | 0.82 | HCAR3 (0.46) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL2815194 | 0.82 | HCAR3 (0.62) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL1906313 | 0.82 | HCAR3 (0.77) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 | |
| SCHEMBL3385901 | 0.82 | HPGD (0.58) | HCAR3ALDH1A1HSD17B10KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737449-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025002177-A1 | P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-01-02 | — | — | WO | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2006121719-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL, GMBH (DE) | 2006-11-16 | — | — | WO | disclosed |
| US-6972297-B2 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-12-06 | — | — | US | disclosed |
| EP-1054867-B1 | ANTIVIRALS | MEDIVIR AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | MEDIVIR AB (SE) | 2003-06-26 | — | — | US | disclosed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | disclosed |
| EP-1268443-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SmithKline Beecham p.l.c. (GB) | 2003-01-02 | — | — | EP | disclosed |
| US-6486183-B1 | Antivirals | MEDIVIR AB (SE) | 2002-11-26 | — | — | US | disclosed |
| WO-2001074788-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-10-11 | — | — | WO | disclosed |
| EP-1054867-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999036406-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | HCAR3 940/4885ALDH1A1 1967/4885HSD17B10 1578/4885 |
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | RAD1, POLL, PNPO | HCAR3 1098/4885ALDH1A1 1387/4885HSD17B10 1355/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | HCAR3 3585/4885ALDH1A1 1977/4885HSD17B10 3076/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | HCAR3 3585/4885ALDH1A1 1977/4885HSD17B10 3076/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HCAR3 1079/4885ALDH1A1 344/4885HSD17B10 113/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HCAR3 1079/4885ALDH1A1 344/4885HSD17B10 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.